$HRGN
Harvard Apparatus Regenerative Technology Inc Stock $hrgn

$hrgn Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000114420418058731 Filed on November 09, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cost Of Revenue			$0.00
YoY Change			-100.0%
Gross Profit			$0.00
YoY Change			-100.0%
Gross Profit Margin
Selling, General & Admin	$952.0K	$940.0K	$970.0K
YoY Change	-1.86%	5.86%	-21.14%
% of Gross Profit
Research & Development	$1.148M	$1.288M	$470.0K
YoY Change	144.26%	-45.52%	-79.74%
% of Gross Profit
Depreciation & Amortization	$67.00K	$64.00K	$80.00K
YoY Change	-16.25%	-28.89%	-27.27%
% of Gross Profit
Operating Expenses	$2.100M	$2.228M	$1.440M
YoY Change	45.83%	-31.49%	-59.46%
Operating Profit		-$2.228M	-$1.440M
YoY Change		-31.49%	-59.81%
Interest Expense	$89.00K	$49.00K	$320.0K
YoY Change	-72.19%	390.0%	33.33%
% of Operating Profit
Other Income/Expense, Net	$176.0K	$139.0K	-$110.0K
YoY Change	-260.0%	1444.44%	-145.64%
Pretax Income	-$1.835M	-$2.089M	-$1.230M
YoY Change	49.19%	-35.58%	-63.2%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$1.835M	-$2.089M	-$1.230M
YoY Change	49.19%	-35.58%	-63.2%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$322.8K	-$368.7K	-$608.9K
COMMON SHARES
Basic Shares Outstanding	5.669M shares	5.663M shares	39.79M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.305M	$3.543M	$4.040M
YoY Change	-67.7%	170.46%	37.41%
Cash & Equivalents	$1.355M	$3.543M	$4.038M
Short-Term Investments
Other Short-Term Assets	$90.00K	$44.00K	$106.0K
YoY Change	-15.09%	-83.94%	-50.0%
Inventory
Prepaid Expenses		$229.0K	$289.0K
Receivables	$176.0K	$90.00K	$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.154M	$3.906M	$4.413M
YoY Change	-51.19%	132.78%	26.59%
LONG-TERM ASSETS
Property, Plant & Equipment	$479.0K	$544.0K	$632.0K
YoY Change	-24.21%	-38.18%	-40.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$479.0K	$544.0K	$632.0K
YoY Change	-24.21%	-37.61%	-40.66%
TOTAL ASSETS
Total Short-Term Assets	$2.154M	$3.906M	$4.413M
Total Long-Term Assets	$479.0K	$544.0K	$632.0K
Total Assets	$2.633M	$4.450M	$5.045M
YoY Change	-47.81%	74.51%	10.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$160.0K	$204.0K	$923.0K
YoY Change	-82.67%	-83.14%	-4.05%
Accrued Expenses	$404.0K	$547.0K	$380.0K
YoY Change	6.32%	3.21%	-68.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$662.0K	$938.0K	$1.622M
YoY Change	-59.19%	-54.82%	-41.59%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$662.0K	$938.0K	$1.622M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$662.0K	$938.0K	$1.622M
YoY Change	-59.19%	-54.82%	-41.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$55.76M	-$53.93M	-$48.23M
YoY Change	15.61%	14.73%	32.81%
Common Stock	$57.00K	$57.00K	$25.00K
YoY Change	128.0%	-85.68%	-85.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.971M	$3.512M	$3.423M
YoY Change
Total Liabilities & Shareholders Equity	$2.633M	$4.450M	$5.045M
YoY Change	-47.81%	74.3%	10.85%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q4
OPERATING ACTIVITIES
Net Income	-$1.835M	-$2.089M	-$1.230M
YoY Change	49.19%	-35.58%	-63.2%
Depreciation, Depletion And Amortization	$67.00K	$64.00K	$80.00K
YoY Change	-16.25%	-28.89%	-27.27%
Cash From Operating Activities	-$2.184M	-$2.224M	-$1.650M
YoY Change	32.36%	-29.84%	-44.82%
INVESTING ACTIVITIES
Capital Expenditures	-$4.000K	-$37.00K	$0.00
YoY Change		270.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$4.000K
YoY Change
Cash From Investing Activities	-$4.000K	-$33.00K	$0.00
YoY Change		230.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	2.000K	4.380M
YoY Change	-100.0%	-99.81%
NET CHANGE
Cash From Operating Activities	-2.184M	-2.224M	-1.650M
Cash From Investing Activities	-4.000K	-33.00K	0.000
Cash From Financing Activities	0.000	2.000K	4.380M
Net Change In Cash	-2.188M	-2.255M	2.730M
YoY Change	-180.15%	6.87%	-189.22%
FREE CASH FLOW
Cash From Operating Activities	-$2.184M	-$2.224M	-$1.650M
Capital Expenditures	-$4.000K	-$37.00K	$0.00
Free Cash Flow	-$2.180M	-$2.187M	-$1.650M
YoY Change	32.12%	-30.79%	-43.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	us-gaap	Assets Assets	5045000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	204000	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	57000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	25000	USD
CY2018Q3	us-gaap	Cash Cash	3543000	USD
CY2017Q4	us-gaap	Cash Cash	4038000	USD
CY2018Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	229000	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	289000	USD
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	57383000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	50157000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-53928000	USD
CY2018Q3	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	90000	USD
CY2017Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	0	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-48234000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	3512000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4450000	USD
CY2018Q3	us-gaap	Other Assets Current OtherAssetsCurrent	44000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	86000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	3906000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	4413000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	544000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	632000	USD
CY2018Q3	us-gaap	Assets Assets	4450000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	923000	USD
CY2018Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	547000	USD
CY2017Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	383000	USD
CY2018Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2017Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	300000	USD
CY2018Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	187000	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	16000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	938000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1622000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	938000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	1622000	USD
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5045000	USD
CY2018Q1	bstg	Maximum Research And Development Expenses Reimbursement MaximumResearchAndDevelopmentExpensesReimbursement	225000	USD
CY2017Q4	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4100000	USD
CY2017Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2100000	USD
CY2018Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3600000	USD
CY2018Q2	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	900000	USD
CY2018Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	250000	shares
CY2018Q3	us-gaap	Revenues Revenues	0	USD
CY2017Q3	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1000000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3400000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	800000	USD
CY2018Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	187000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	16000	USD
CY2018Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.00
CY2017Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.00
CY2018Q3	us-gaap	Share Price SharePrice	3.12
CY2017Q4	us-gaap	Share Price SharePrice	0.87
CY2018Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	92212	shares
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	92212	shares
	bstg	Product Distribution Agreement Term ProductDistributionAgreementTerm	P10Y
CY2018Q1	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	300000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5642451	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1276099	shares
CY2017Q4	us-gaap	Restructuring And Related Cost Expected Number Of Positions Eliminated RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated	20	pure
CY2017Q4	us-gaap	Restructuring Costs RestructuringCosts	99000	USD
CY2018Q1	bstg	Percentage Of Salary Of Officers On Contracted Rate PercentageOfSalaryOfOfficersOnContractedRate	0.8	pure
CY2018Q1	us-gaap	Payments For Postemployment Benefits PaymentsForPostemploymentBenefits	99000	USD
	us-gaap	Revenues Revenues	0	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1288000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2364000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2768000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7121000	USD
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	940000	USD
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	888000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2973000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2906000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	2228000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	3252000	USD
	us-gaap	Operating Expenses OperatingExpenses	5741000	USD
	us-gaap	Operating Expenses OperatingExpenses	10027000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2228000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3252000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5741000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10027000	USD
CY2018Q3	bstg	Grant Income GrantIncome	90000	USD
CY2017Q3	bstg	Grant Income GrantIncome	0	USD
	bstg	Grant Income GrantIncome	225000	USD
	bstg	Grant Income GrantIncome	0	USD
CY2018Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-49000	USD
CY2017Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-9000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	171000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	660000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-2089000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-3243000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-5694000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-10687000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.66
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.40
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.21
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5666000	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1948000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4056000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1722000	shares
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	139000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	47000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-660000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	461000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	591000	USD
	us-gaap	Depreciation Depreciation	194000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2941000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3543000	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	7000	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
	bstg	Fair Value Of Warrant Liability Reclassified To Additional Paid In Capital FairValueOfWarrantLiabilityReclassifiedToAdditionalPaidInCapital	0	USD
	us-gaap	Depreciation Depreciation	334000	USD
	bstg	Fair Value Adjustment Of Warrants Gross FairValueAdjustmentOfWarrantsGross	171000	USD
	bstg	Fair Value Adjustment Of Warrants Gross FairValueAdjustmentOfWarrantsGross	660000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-42000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-53000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-135000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	90000	USD
	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	0	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-721000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	246000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	164000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-681000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5454000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9360000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	127000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	140000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	64000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-63000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-140000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	300000	USD
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	0	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	5322000	USD
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	6801000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5022000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7869000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-495000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1631000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4038000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1310000	USD
	bstg	Fair Value Of Liability Warrants Issued In Connection With Issuance Of Common Stock FairValueOfLiabilityWarrantsIssuedInConnectionWithIssuanceOfCommonStock	0	USD
	bstg	Fair Value Of Liability Warrants Issued In Connection With Issuance Of Common Stock FairValueOfLiabilityWarrantsIssuedInConnectionWithIssuanceOfCommonStock	3787000	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	2000	USD
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	0	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	3423000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	461000	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5271000	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	51000	USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
CY2017Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	USD
	bstg	Fair Value Of Warrant Liability Reclassified To Additional Paid In Capital FairValueOfWarrantLiabilityReclassifiedToAdditionalPaidInCapital	4327000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-8000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1475000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	bstg	Stock Issued During The Period Conversion Of Preferred Stock StockIssuedDuringThePeriodConversionOfPreferredStock	0	USD
CY2018Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	51000	USD
CY2018Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3.60
CY2018Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	3.60
	us-gaap	Officers Compensation OfficersCompensation	104000	USD
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000000	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000000	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5668733000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2507304000	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5668733000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2507304000	shares
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1059000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	9000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.88	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.18	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0265	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0282	pure
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	194000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	194000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	461000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	591000	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1600000	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	2098000	shares
CY2017Q4	us-gaap	Restructuring And Related Cost Description RestructuringAndRelatedCostDescription	In addition, officers of the Company agreed to a temporary reduction and deferral in their salaries of 50% effective November 2017
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	Biostage, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0001563665
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Trading Symbol TradingSymbol	BSTG
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5668733	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Small Business EntitySmallBusiness	true

Files In Submission

Name	View Source	Status
0001144204-18-058731-index-headers.html	Edgar Link	pending
0001144204-18-058731-index.html	Edgar Link	pending
0001144204-18-058731.txt	Edgar Link	pending
0001144204-18-058731-xbrl.zip	Edgar Link	pending
bstg-20180930.xml	Edgar Link	completed
bstg-20180930.xsd	Edgar Link	pending
bstg-20180930_cal.xml	Edgar Link	unprocessable
bstg-20180930_def.xml	Edgar Link	unprocessable
bstg-20180930_lab.xml	Edgar Link	unprocessable
bstg-20180930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv506123_10q.htm	Edgar Link	pending
tv506123_ex31-1.htm	Edgar Link	pending
tv506123_ex31-2.htm	Edgar Link	pending
tv506123_ex32-1.htm	Edgar Link	pending
tv506123_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HRGN
Harvard Apparatus Regenerative Technology Inc Stock $hrgn

2018 Q4 Form 10-Q Financial Statement

#000114420418058731 Filed on November 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HRGN Harvard Apparatus Regenerative Technology Inc Stock $hrgn

2018 Q4 Form 10-Q Financial Statement

#000114420418058731 Filed on November 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HRGN
Harvard Apparatus Regenerative Technology Inc Stock $hrgn